PTGXのチャート
PTGXの企業情報
| symbol | PTGx |
|---|---|
| 会社名 | Protagonist Therapeutics Inc （プロタゴニスト・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 プロタゴニスト・セラピューティクス(Protagonist Therapeutics Inc.)は臨床病期のバイオ医薬品会社である。同社は満たされない医療ニーズに対応するために、ペプチドベースの新化学物質(NCEs)発見と開発を行うペプチド技術プラットフォームを有する。同社の製品パイプラインには、PTG-100、PTG-200、PTG-300がある。主要目標は、市販されていた注射可能な抗体医薬を標的とする生物学的経路を標的とする経口ペプチド薬物の開発である。PTG-100は、健康な志願者（NHV）において第I相臨床試験を完了した経口α-4-β-7（a4b7）インテグリン特異的アンタゴニストペプチド産物候補であり、中等度から重度の潰瘍性大腸炎（UC）の治療のために開発されている。PTG-200は、中等度から重度のクローン病（CD）のために開発された経口インターロイキン23受容体（IL-23R）アンタゴニストであり、研究を可能にする治験薬（IND）である。PTG-300は、鉄過剰症に関連する希少疾患の治療用の注射可能なヘプシジン模倣物である。 プロタゴニスト・セラピュ―ティクスは米国のバイオ医薬品企業。医療ニ―ズに対処するため、臨床段階でペプチド系新薬の開発に従事する。従来の注射による抗体薬と同じ治療効果を目指して経口型ペプチド新薬を開発し、患者の負担軽減を図る。主に、炎症性腸疾患の治療向けに経口ペプチド薬を開発する。本社はカリフォルニア州ミルピタス。 Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. Rusfertide (PTG-300) is an injectable hepcidin mimetic in a Phase 2 proof-of-concept clinical trial for polycythemia vera, and a separate Phase 2 clinical study for hereditary hemochromatosis. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in a 150 patient Phase 2 study for the potential treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease. Two additional second-generation oral interleukin-23 receptor antagonist candidates PN-235 and PN-232, are in early stages of clinical development. The Company has developed a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms. |
| 本社所在地 | 7707 Gateway Boulevard Suite 140 Newark CA 94560-1160 USA |
| 代表者氏名 | Harold E. Selick ハロルドE.セリック |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 510-474-0170 |
| 設立年月日 | 38930 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2016年 |
| 従業員数 | 55人 |
| url | www.protagonist-inc.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ptgx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -25.48800 |
| 終値（lastsale） | 9.4 |
| 時価総額（marketcap） | 226404527.2 |
| 時価総額 | 時価総額（百万ドル） 208.34030 |
| 売上高 | 売上高（百万ドル） 42.51800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 83.17330 |
| 当期純利益 | 当期純利益（百万ドル） -24.20100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Protagonist Therapeutics Inc revenues increased from $0K to $22.5M. Net loss decreased 44% to $16.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest income increase from $324K to $1.1M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.73 to -$0.77. |
PTGXのテクニカル分析
PTGXのニュース
Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference 2022/12/21 21:05:00 PR Newswire
NEWARK, Calif., Dec. 21, 2022 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will offer a corporate presentation and host one-on-one meetings with investors…
These strategies will help Protagonist Therapeutics Inc. (PTGX) succeed 2022/12/09 13:40:00 US Post News
Protagonist Therapeutics Inc. (NASDAQ:PTGX) marked $7.78 per share on Thursday, up from a previous closing price of $7.65. While Protagonist Therapeutics Inc. has overperformed by 1.70%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PTGX fell by -77.14%, with highs and lows ranging from $37.04 to […]
Short Volatility Alert: PROTAGONIST THERAP 2022/11/16 19:27:04 Benzinga
On Tuesday, shares of PROTAGONIST THERAP (NASDAQ: PTGX ) experienced volatile short activity. After the activity, the stock price went down -3.25% to $8.04. The overall sentiment for PTGX has been Bearish. The signal from the volatility alert is trending Bullish. Therefore, the recommendation is to Strong Buy. The volatility alert was produced on the prior trading date, 11/15/2022 with a volatility change of +36.45%. The current volatility indicator stands at 8.196. Overview: The securities lending volatility indicator is produced by Tidal Markets, in partnership with Benzinga Insights. Securities lending primarily serves the … Full story available on Benzinga.com
Results from Protagonist Therapeutics Inc. (PTGX) show risk 2022/11/10 15:00:00 US Post News
Protagonist Therapeutics Inc. (NASDAQ:PTGX) marked $7.71 per share on Wednesday, down from a previous closing price of $7.74. While Protagonist Therapeutics Inc. has underperformed by -0.39%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PTGX fell by -78.29%, with highs and lows ranging from $38.11 to […]
Protagonist GAAP EPS of -$0.64 beats by $0.23 2022/11/08 22:44:29 Seeking Alpha
Protagonist press release (PTGX): Q3 GAAP EPS of -$0.64 beats by $0.23.The company expects current cash, cash equivalents and marketable securities of $267.4M to be sufficient to…
Protagonist Therapeutics (PTGX) Investor Presentation - Slideshow (NASDAQ:PTGX) 2022/08/05 20:04:41 Seeking Alpha
The following slide deck was published by Protagonist Therapeutics, Inc.
Protagonist GAAP EPS of -$0.84 beats by $0.10 2022/08/04 21:34:25 Seeking Alpha
Protagonist press release (PTGX): Q2 GAAP EPS of -$0.84 beats by $0.10.Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of June…
Have you been able to find a good deal on Protagonist Therapeutics Inc.’s shares? 2022/08/04 15:48:00 US Post News
The share price of Protagonist Therapeutics Inc. (NASDAQ:PTGX) rose to $11.21 per share on Wednesday from $10.63. While Protagonist Therapeutics Inc. has overperformed by 5.46%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PTGX fell by -77.24%, with highs and lows ranging from $50.54 to $6.91, […]
Why Protagonist Therapeutics Inc. (NASDAQ: PTGX) Stock Should Not Be Discarded By Investors In 2022 2022/07/12 13:30:00 Marketing Sentinel
In the last trading session, 1.52 million shares of the Protagonist Therapeutics Inc. (NASDAQ:PTGX) were traded, and its beta was 2.51. Most recently the company’s share price was $9.00, and it changed around -$0.62 or -6.44% from the last close, which brings the market valuation of the company to $389.70M. PTGX currently trades at a … Why Protagonist Therapeutics Inc. (NASDAQ: PTGX) Stock Should Not Be Discarded By Investors In 2022 Read More »
Protagonist Therapeutics (PTGX) Presents At Jefferies Healthcare Conference - Slideshow (NASDAQ:PTGX) 2022/06/15 15:55:27 Seeking Alpha
The following slide deck was published by Protagonist Therapeutics, Inc.
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update 2022/02/28 21:05:00 PR Newswire
NEWARK, Calif., Feb. 28, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. "This past quarter and the year leading up…
Protagonist Therapeutics Inc. (NASDAQ:PTGX) Is Likely To Perform Well Over The Long Term. Lost Nearly -13.83% Last Month. 2022/02/26 15:00:00 Marketing Sentinel
In last trading session, Protagonist Therapeutics Inc. (NASDAQ:PTGX) saw 0.54 million shares changing hands with its beta currently measuring 2.28. Company’s recent per share price level of $24.49 trading at $0.24 or 0.99% at ring of the bell on the day assigns it a market valuation of $1.20B. That closing price of PTGX’s stock is … Protagonist Therapeutics Inc. (NASDAQ:PTGX) Is Likely To Perform Well Over The Long Term. Lost Nearly -13.83% Last Month. Read More »
Protagonist Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference 2022/02/10 12:00:00 Kwhen Finance
Protagonist Therapeutics, Inc. (PTGX) Fell Out Of Favor With Hedge Funds 2022/01/12 16:26:26 Insider Monkey
In this article we will check out the progression of hedge fund sentiment towards Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and determine whether it is a good investment right now.
Protagonist Therapeutics (NASDAQ:PTGX) versus Syndax Pharmaceuticals (NASDAQ:SNDX) Financial Survey 2021/12/22 08:14:42 Dakota Financial News
Protagonist Therapeutics (NASDAQ:PTGX) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings. Profitability This table compares Protagonist Therapeutics and Syndax Pharmaceuticals net margins, return on equity and []